VKH
BCRX icon

Virtu KCG Holdings’s BioCryst Pharmaceuticals BCRX Stock Holding History

Virtu KCG Holdings’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-21,227
Closed -$178K – 2891
2017
Q1 		$178K Sell
21,227
-8,014
-27% -$55.7K ﹤0.01% 2488
2016
Q4 		$185K Sell
29,241
-3,083
-10% -$16K ﹤0.01% 2640
2016
Q3 		$143K Buy
32,324
+21,813
+208% +$87.1K ﹤0.01% 2517
2016
Q2 		$30K Sell
10,511
-17,653
-63% -$54.8K ﹤0.01% 2751
2016
Q1 		$80K Buy
+28,164
New +$125K ﹤0.01% 2369
2015
Q2 		– Sell
-13,637
Closed -$123K – 3320
2015
Q1 		$123K Buy
+13,637
New +$141K ﹤0.01% 2594
2014
Q4 		– Sell
-43,216
Closed -$422K – 3739
2014
Q3 		$422K Buy
43,216
+28,895
+202% +$354K 0.01% 1892
2014
Q2 		$182K Buy
+14,321
New +$139K ﹤0.01% 3107
2013
Q4 		– Sell
-11,614
Closed -$85K – 3789
2013
Q3 		$85K Buy
+11,614
New +$58.9K ﹤0.01% 3402

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Virtu KCG Holdings's BCRX Position: Q2 2017 in Review

Virtu KCG Holdings sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2017, closing a stake of 21,227 shares — an estimated $178K sold.

Virtu KCG Holdings first reported a position in BCRX in Q3 2013 and held it in 9 quarters. The position peaked at $422K in Q3 2014. 115 funds tracked by Wall St. Rank hold BCRX as of Q2 2017.

  • Virtu KCG Holdings reported no remaining BioCryst Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 21,227 BioCryst Pharmaceuticals shares in Q2 2017, an estimated $178K.
  • Virtu KCG Holdings first reported a position in BioCryst Pharmaceuticals in Q3 2013 and held it in 9 quarters.
  • Virtu KCG Holdings's BioCryst Pharmaceuticals position peaked at $422K in Q3 2014.
  • 115 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.